FDA Proposes Exempting Medical Devices from Premarket Notification

The U.S. Food and Drug Administration has issued new draft guidance that would exempt certain Class I and II medical devices from premarket submission requirements.

Get access to this article and thousands more...

All Health Data Management articles are archived after 7 days. REGISTER NOW for unlimited access to all recently archived articles, as well as thousands of searchable stories. Registered Members also gain access to exclusive industry white paper downloads, web seminars, podcasts, e-books, and conference discounts. Qualified members may also choose to receive our free monthly magazine and any of our e-newsletters covering the latest breaking news, opinions from industry leaders, developing trends and specialized topics like EHR's, revenue cycle management, health insurance exchanges, analytics, and more!

Already Registered?

Forgot Password/Need Help?
Comments (1)
"[...]"This is big news and a huge boost to the mHealth industry," said Bradley Merrill Thompson[...]"

Sorry, perhaps I'm missing something. How does this draft guidance pertain at all to mHealth?

Per the definition of "mHealth", from Wikipedia, the free encyclopedia: "mHealth (also written as m-health) is an abbreviation for mobile health, a term used for the practice of medicine and public health supported by mobile devices."[1]

Looking at the list of Class I and Class II devices included in the guidance, mHealth would seem to be excluded.

In fact, in the guidance, in instances where a device is a computer device, the guidance has the following caveat for each: "If device contains software to analyze clinical implication of the measurement, a 510(k) will be required."

Unless mHealth applies to bandage and gauze, patient restraints, denture fitting tools, or hemorrhoid prevention pressure wedges, this is not big news for anything related to mHealth.

"[...]"It shows that FDA is being extremely practical in reviewing its own practices and updating its regulatory requirements where the risks simply do not merit the investment of regulatory resources. My hat is off to FDA."[...]"

I agree that it is nice to see that the FDA can be practical and pragmatic in its diligence.

[1] mHealth, from Wikipedia, the free encyclopedia en.wikipedia.org/wiki/MHealth
Posted by Ken W | Tuesday, August 05 2014 at 12:49PM ET
Add Your Comments:
Not Registered?
You must be registered to post a comment. Click here to register.
Already registered? Log in here
Please note you must now log in with your email address and password.


Slide Shows

Already a subscriber? Log in here
Please note you must now log in with your email address and password.